['arthritis, psoriatic']
['placebo', 'golimumab']

        Inclusion Criteria:

          -  Have had psoriatic arthritis (PsA) for at least 6 months prior to the first
             administration of study agent

          -  Have a diagnosis of active PSA as defined by 5 or more swollen joints and 5 or more
             tender joints at Screening and at Baseline and C-reactive protein >=0.6 milligram per
             deciliter (mg/dL) at Screening

          -  Have active plaque psoriasis or a documented history of plaque psoriasis

          -  Have active PsA despite current or previous disease-modifying antirheumatic drugs
             (DMARD) and/or nonsteroidal anti-inflammatory drug (NSAID) therapy. DMARD therapy is
             defined as taking a DMARD for at least 3 months, or evidence of DMARD intolerance.
             NSAID therapy is defined as taking an NSAID for at least 4 weeks or evidence of NSAID
             intolerance

        Exclusion Criteria:

          -  Have other inflammatory diseases that might confound the evaluations of benefit of
             Golimumab therapy, including but not limited to rheumatoid arthritis, ankylosing
             spondylitis, systemic lupus erythematosus, or Lyme disease

          -  Are pregnant, nursing, or planning a pregnancy or fathering a child while enrolled in
             the study or within 4 months after receiving the last administration of study agent

          -  Have used any biologic agents that are targeted for reducing tumor necrosis factors
             (TNF) alpha, including but not limited to Infliximab, Etanercept, Adalimumab,
             Golimumab, and Certolizumab Pegol

          -  Have ever used cytotoxic drugs, including Chlorambucil, Cyclophosphamide, Nitrogen
             mustard, or other Alkylating agents
      